| Dr Kevin B Strom, MD | |
|
1100 E 26th St, Sioux Falls, SD 57105-4023 | |
| (605) 338-7098 | |
| (605) 335-3505 |
| Full Name | Dr Kevin B Strom |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 32 Years |
| Location | 1100 E 26th St, Sioux Falls, South Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801836481 | NPI | - | NPPES |
| 5701010 | Medicaid | SD | |
| 0007925 | Other | SD | BLUE CROSS SD |
| 44F69ST | Other | MN | BLUE CROSS MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 4847 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Avera Mckennan Hospital & University Health Center | Sioux falls, SD | Hospital |
| Sioux Falls Specialty Hospital | Sioux falls, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesiology Associates, Inc. | 2668364548 | 25 |
News Archive
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
Cancer patients receiving care in geographically dispersed urban and rural oncology practices who participated in a program that included telephone-based care management and home-based automated symptom monitoring had greater improvement in pain and depression compared to patients who received usual care, according to a study in the July 14 issue of JAMA.
GI Dynamics Inc., a medical device company that is developing EndoBarrier for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, "Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic Patients with Obesity: A Meta-analysis with Secondary Analysis on Weight Loss and Hormonal Changes," by Pichamol Jirapinyo, MD, of Brigham and Women's Hospital in Boston, Massachusetts, and Diplomat of the American Board of Obesity Medicine, has been published in Diabetes Care, the journal of the American Diabetes Association.
To understand where fat comes from, you have to start with a skinny mouse. By using such a creature, and observing the growth of fat after injections of different kinds of immature cells, Rockefeller University scientists have discovered an important fat precursor cell that may in time explain how changes in the numbers of fat cells might increase and lead to obesity.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that a blinded, multi-center clinical study of the CellDetect non-invasive test for detecting bladder cancer in urine, successfully achieved the study's primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of the disease.
› Verified 3 days ago
| Entity Name | Anesthesiology Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477622215 PECOS PAC ID: 2668364548 Enrollment ID: O20040325001701 |
News Archive
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
Cancer patients receiving care in geographically dispersed urban and rural oncology practices who participated in a program that included telephone-based care management and home-based automated symptom monitoring had greater improvement in pain and depression compared to patients who received usual care, according to a study in the July 14 issue of JAMA.
GI Dynamics Inc., a medical device company that is developing EndoBarrier for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, "Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic Patients with Obesity: A Meta-analysis with Secondary Analysis on Weight Loss and Hormonal Changes," by Pichamol Jirapinyo, MD, of Brigham and Women's Hospital in Boston, Massachusetts, and Diplomat of the American Board of Obesity Medicine, has been published in Diabetes Care, the journal of the American Diabetes Association.
To understand where fat comes from, you have to start with a skinny mouse. By using such a creature, and observing the growth of fat after injections of different kinds of immature cells, Rockefeller University scientists have discovered an important fat precursor cell that may in time explain how changes in the numbers of fat cells might increase and lead to obesity.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that a blinded, multi-center clinical study of the CellDetect non-invasive test for detecting bladder cancer in urine, successfully achieved the study's primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of the disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kevin B Strom, MD 5004 S Lewis Ave, Sioux Falls, SD 57108-4713 Ph: (605) 335-6386 | Dr Kevin B Strom, MD 1100 E 26th St, Sioux Falls, SD 57105-4023 Ph: (605) 338-7098 |
News Archive
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
Cancer patients receiving care in geographically dispersed urban and rural oncology practices who participated in a program that included telephone-based care management and home-based automated symptom monitoring had greater improvement in pain and depression compared to patients who received usual care, according to a study in the July 14 issue of JAMA.
GI Dynamics Inc., a medical device company that is developing EndoBarrier for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, "Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic Patients with Obesity: A Meta-analysis with Secondary Analysis on Weight Loss and Hormonal Changes," by Pichamol Jirapinyo, MD, of Brigham and Women's Hospital in Boston, Massachusetts, and Diplomat of the American Board of Obesity Medicine, has been published in Diabetes Care, the journal of the American Diabetes Association.
To understand where fat comes from, you have to start with a skinny mouse. By using such a creature, and observing the growth of fat after injections of different kinds of immature cells, Rockefeller University scientists have discovered an important fat precursor cell that may in time explain how changes in the numbers of fat cells might increase and lead to obesity.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that a blinded, multi-center clinical study of the CellDetect non-invasive test for detecting bladder cancer in urine, successfully achieved the study's primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of the disease.
› Verified 3 days ago
Dr. David B Munce, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1100 E 26th St, Sioux Falls, SD 57105 Phone: 605-338-7098 Fax: 605-335-3505 | |
James T Brunz, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 810 E 23rd St, Sioux Falls, SD 57105 Phone: 605-331-5890 Fax: 605-336-3974 | |
Robert J Lunn, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1305 W 18th St, Sioux Falls, SD 57105 Phone: 605-338-5488 | |
David Thomas Porembka, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1325 S Cliff Ave, Sioux Falls, SD 57105 Phone: 605-322-2460 Fax: 605-322-2470 | |
Dr. Michael R Schroeder, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1100 E 26th St, Sioux Falls, SD 57105 Phone: 605-338-7098 Fax: 605-335-3505 | |
Victor Leslie James Scott, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1315 S. Cliff Ave., Ste. 1100, Sioux Falls, SD 57105 Phone: 605-322-7350 Fax: 605-322-7351 | |
David J Dingsor, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1305 W 18th St, Sioux Falls, SD 57105 Phone: 605-338-5488 |